Drug intelligence / Profile preview

huangjingjiannao prescription

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Huangjingjiannao prescription is a Traditional Chinese Medicine (TCM) herbal formula developed by Guang'anmen Hospital for the treatment of vascular mild cognitive impairment (vMCI). The formula is primarily composed of *Polygonatum sibiricum* (Huangjing) and other traditional herbs intended to tonify the kidney and invigorate the brain. It is currently being evaluated in clinical trials (e.g., ChiCTR2200061393) to assess its efficacy compared to donepezil, focusing on cognitive improvement, daily functioning, and changes in brain connectivity and structure as visualized by multimodality MRI.

Other names: Huangjing Jiannao formulaHuangjing Jiannao Fanghuangjingjiannao prescription

Targets

GluR (Glutamate receptors)

Beyond the preview

Go deeper on huangjingjiannao prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on huangjingjiannao prescription.

Explore the full profile